PHPeter M. Hawkey

Peter M. Hawkey

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Peter M. Hawkey has a total of 163 co-authors. Here are the top co-authors by number of shared publications:

  • Savita Gossain

    Public Health England, Public Health Laboratory Birmingham, Heartlands Hospital, Bordesley Green East, Birmingham, B9 5SS, UK

    3 shared publications
  • Ala Szczepura

    Centre for Healthcare and Communities, Coventry University, Coventry, UK

    2 shared publications
  • Fang Gao Smith

    Department of Inflammation and Ageing, School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham, Birmingham, UK

    2 shared publications
  • J. T. Evans

    Antimicrobial Agents Research Group , Institute of Biomedical Research, University of Birmingham , Vincent Drive, Edgbaston, Birmingham B15 2TT , UK 2 West Midlands Health Protection Agency, Heart of England NHS Foundation Trust , Heartlands Hospital , Bordesley Green East, Birmingham B9 5SS , UK

    2 shared publications
  • Katherine J. Hardy

    West Midlands Public Health Laboratory, Heart of England NHS Foundation Trust, Birmingham, UK

    2 shared publications
  • L. Xu

    School of Immunity and Infection, College of Medical and Dental Sciences , University of Birmingham , Birmingham B15 2TT , UK 3 HPA Public Health Laboratory Birmingham , Heart of England NHS Foundation Trust , Birmingham B9 5SS , UK

    2 shared publications

Latest Publications

  • Open Access

    Use of antimicrobial resistance information and prescribing guidance for management of urinary tract infections: survey of general practitioners in the West Midlands

    by Dean Ironmonger, Obaghe Edeghere, Savita Gossain, Peter M. Hawkey

    There is a marked variation in both antibiotic prescribing practice and urine sampling rates for diagnostic microbiology across general practices in England. To help understand factors driving this variation, we undertook a survey in 2012/13 to determine sampling protocols and antibiotic formularies used by general practitioners (GPs) for managing urinary tract infections (UTIs) in the West Midlands region of England. Cross-sectional survey of all eligible general practices in the West Midlands region of England undertaken in November 2012. GPs were invited to complete an online survey questionnaire to gather information on policies used within the practice for urine sampling for microbiological examination, and the source of antibiotic formularies used to guide treatment of UTIs. The questionnaire also gathered information on how they would manage five hypothetical clinical scenarios encountered in the community. The response rate was 11.3 % (409/3635 GPs), equivalent to a practice response rate of 26 % (248/950). Only 50 % of GPs reported having a practice policy for urine sampling. Although there was good agreement from GPs regarding collecting specimens in scenarios symbolising treatment failure (98 %), UTI in an adult male (98 %) and asymptomatic UTI in pregnancy (97 %), there was variation in GPs requesting a specimen for the scenarios involving a suspected uncomplicated urinary tract infection (UTI) and an asymptomatic catheterised elderly patient; with 40 and 38 % respectively indicating they would collect a specimen for microbiological examination. Standardised evidence based clinical management policies and antibiotic formularies for GPs should be readily available. This will promote the rational use of diagnostic microbiology services, improve antimicrobial stewardship and aid the interpretation of ongoing antimicrobial resistance surveillance.


  • Open Access

    Rapid draft sequencing and real-time nanopore sequencing in a hospital outbreak of Salmonella

    by Joshua Quick, Philip Ashton, Szymon Calus, Carole Chatt, Savita Gossain, Jeremy Hawker, Satheesh Nair, Keith Neal, Kathy Nye, Tansy Peters, et al.

    Background: Foodborne outbreaks of Salmonella remain a pressing public health concern. We recently detected a large outbreak of Salmonella enterica serovar Enteritidis phage type 14b affecting more than 30 patients in our hospital. This outbreak was linked to community, national and European-wide cases. Hospital patients with Salmonella are at high risk, and require a rapid response. We initially investigated this outbreak by whole-genome sequencing using a novel rapid protocol on the Illumina MiSeq; we then integrated these data with whole-genome data from surveillance sequencing, thereby placing the outbreak in a national context. Additionally, we investigated the potential of a newly released sequencing technology, the MinION from Oxford Nanopore Technologies, in the management of a hospital outbreak of Salmonella. Results: We demonstrate that rapid MiSeq sequencing can reduce the time to answer compared to the standard sequencing protocol with no impact on the results. We show, for the first time, that the MinION can acquire clinically relevant information in real time and within minutes of a DNA library being loaded. MinION sequencing permits confident assignment to species level within 20 min. Using a novel streaming phylogenetic placement method samples can be assigned to a serotype in 40 min and determined to be part of the outbreak in less than 2 h. Conclusions: Both approaches yielded reliable and actionable clinical information on the Salmonella outbreak in less than half a day. The rapid availability of such information may facilitate more informed epidemiological investigations and influence infection control practices.


  • Open Access

    How do hospital professionals involved in a randomised controlled trial perceive the value of genotyping vs. PCR-ribotyping for control of hospital acquired C. difficile infections?

    by Ala Szczepura, Susan Manzoor, Katherine Hardy, Nigel Stallard, Helen Parsons, Savita Gossain, Peter M Hawkey

    Despite scientific advances in typing of C. difficile strains very little is known about how hospital staff use typing results during periods of increased incidence (PIIs). This qualitative study, undertaken alongside a randomised controlled trial (RCT), explored this issue. The trial compared ribotyping versus more rapid genotyping (MLVA or multilocus variable repeat analysis) and found no significant difference in post 48 hour cases (C difficile transmissions).

  • Open Access

    Molecular Epidemiology of Clostridium difficile Infection in a Major Chinese Hospital: an Underrecognized Problem in Asia?

    by Peter M. Hawkey, Clare Marriott, Wen En Liu, Zi Juan Jian, Qian Gao, Thomas Kin Wah Ling, Viola Chow, Erica So, Raphael Chan, Katie Hardy, et al.

    Clostridium difficile infection is almost unrecognized in mainland China. We have undertaken a study in a large Chinese teaching hospital in Changsha, Hunan, China, to identify cases of C. difficile , record patient characteristics, and define the molecular epidemiology with respect to ribotype distribution and cross-infection. Between April 2009 and February 2010, we examined fecal samples from 70 hospitalized patients with diarrhea who were receiving or had received antibiotics within the previous 6 weeks. Clinical information was collected and the samples were cultured for C. difficile retrospectively. Isolates were ribotyped, and multiple-locus variable-number tandem-repeat assay (MLVA) subtyping was performed on clusters of the same ribotype. The mean age of patients from whom C. difficile was cultured was 58 years, with only 4/21 patients aged >65 years. All patients, with a single exception, had received a third-generation cephalosporin and/or a quinolone antibiotic. Twenty-one isolates of C. difficile were recovered, and seven different ribotypes were identified, the dominant types being 017 (48%), 046 (14%), and 012 (14%). We identified two clusters of cross-infection with indistinguishable isolates of ribotype 017, with evidence of spread both within and between wards. We have identified C. difficile as a possibly significant problem, with cross-infection and a distinct ribotype distribution, in a large Chinese hospital. C. difficile may be underrecognized in China, and further epidemiological studies across the country together with the introduction of routine diagnostic testing are needed to ascertain the size of this potentially significant problem.


  • Open Access

    Epidemiology of Clostridium difficile infection in Asia

    by Deirdre A Collins, Peter M Hawkey, Thomas V Riley

    While Clostridium difficile infection (CDI) has come to prominence as major epidemics have occurred in North America and Europe over the recent decade, awareness and surveillance of CDI in Asia have remained poor. Limited studies performed throughout Asia indicate that CDI is also a significant nosocomial pathogen in this region, but the true prevalence of CDI remains unknown. A lack of regulated antibiotic use in many Asian countries suggests that the prevalence of CDI may be comparatively high. Molecular studies indicate that ribotypes 027 and 078, which have caused significant outbreaks in other regions of the world, are rare in Asia. However, variant toxin A-negative/toxin B-positive strains of ribotype 017 have caused epidemics across several Asian countries. Ribotype smz/018 has caused widespread disease across Japan over the last decade and more recently emerged in Korea. This review summarises current knowledge on CDI in Asian countries.


  • Open Access

    Randomized double-blind placebo-controlled trial of 40 mg/day of atorvastatin in reducing the severity of sepsis in ward patients (ASEPSIS Trial)

    by Jaimin M Patel, Catherine Snaith, David R Thickett, Lucie Linhartova, Teresa Melody, Peter Hawkey, Anthony H Barnett, Alan Jones, Tan Hong, Matthew W Cooke, et al.

    Introduction: Several observational studies suggest that statins modulate the pathophysiology of sepsis and may prevent its progression. The aim of this study was to determine if the acute administration of atorvastatin reduces sepsis progression in statin naïve patients hospitalized with sepsis. Methods: A single centre phase II randomized double-blind placebo-controlled trial. Patients with sepsis were randomized to atorvastatin 40 mg daily or placebo for the duration of their hospital stay up to a maximum of 28-days. The primary end-point was the rate of sepsis progressing to severe sepsis during hospitalization. Results: 100 patients were randomized, 49 to the treatment with atorvastatin and 51 to placebo. Patients in the atorvastatin group had a significantly lower conversion rate to severe sepsis compared to placebo (4% vs. 24% p = 0.007.), with a number needed to treat of 5. No significant difference in length of hospital stay, critical care unit admissions, 28-day and 12-month readmissions or mortality was observed. Plasma cholesterol and albumin creatinine ratios were significantly lower at day 4 in the atorvastatin group (p < 0.0001 and p = 0.049 respectively). No difference in adverse events between the two groups was observed (p = 0.238). Conclusions: Acute administration of atorvastatin in patients with sepsis may prevent sepsis progression. Further multi-centre trials are required to verify these findings. Trial Registration: International Standard Randomized Control Trial Registry ISRCTN64637517.


  • Open Access

    Clinical review: Probiotics in critical care

    by Neil H Crooks, Catherine Snaith, Deborah Webster, Fang Gao, Peter Hawkey

    Patients in ICUs represent a relatively small subgroup of hospitalised patients, but they account for approximately 25% of all hospital infections. Approximately 30% of ICU patients suffer from infection as a complication of critical illness, which increases the length of ICU stay, morbidity, mortality and cost. Gram-negative bacteria are the predominant cause of ICU-related infections and with the rise in multidrug-resistant strains we should focus our attention on nonantibiotic strategies in the prevention and treatment of nosocomial infections. Probiotics have been proposed as one option in this quest; however, mechanisms of action in the critically ill population require further investigation. Some of the beneficial effects appear to be associated with improvement in gastrointestinal barrier function, restoration of normal intestinal permeability and motility, modification of the balance of intestinal microbiota and immunomodulation. However, the information we have to date on the use of probiotics in the critical care setting is difficult to interpret due to small sample sizes, differences in ICU populations, the variety of probiotic combinations studied and differences in administration techniques. In this review we shall examine the use of probiotics in the critical care setting, look at some of the proposed mechanisms of action and discuss their potential benefits and drawbacks.


  • Open Access

    Prevalence and characteristics of -lactamase and plasmid-mediated quinolone resistance genes in Escherichia coli isolated from farmed fish in China

    by Hong-Xia Jiang, Dian Tang, Ya-Hong Liu, Xiao-Hua Zhang, Zhen-Ling Zeng, L. Xu, Peter M. Hawkey

    To determine the molecular epidemiology of extended-spectrum β-lactamases (ESBLs) and plasmid-mediated quinolone resistance (PMQR) in Escherichia coli isolated from farmed fish in China. E. coli was isolated from fish gut samples from fish farmed throughout Guangdong province and tested for the presence of the β-lactamase genes and PMQR-encoding genes using PCR and DNA sequence analysis. Co-transfer of plasmids encoding for ESBLs as well as PMQR determinants was explored by conjugation into E. coli. A total of 218 non-duplicate E. coli were recovered from fish gut samples. β-Lactamase genes were identified in 19 (17%) of 112 strains with reduced susceptibility to ampicillin, and PMQR genes were identified in 59 (73.8%) of 80 strains with reduced susceptibility to ciprofloxacin. Only three ESBL genes were identified in three isolates: blaCTX-M-14, blaCTX-M-79 and blaSHV-27. PMQR gene screening identified qnr genes (n = 59) as the most common, including qnrB (n = 33), qnrS (n = 21) and qnrD (n = 5), with aac(6′)-Ib-cr (n = 6) being rarely found. The co-carriage of two or three PMQR genes in one strain was found in 7 (11.9%) isolates. The ESBL gene blaCTX-M-79 was found to be co-carried with qnrS. Co-transfer of qnrS was observed with blaCTX-M-79. Our study is the first to demonstrate the existence of high levels of mobile genes conferring reduced susceptibility to fluoroquinolones as well as the presence of ESBL genes in fish produced in China, and identifies a significant reservoir of antibiotic resistance genes relevant to human medicine.


  • Carbapenem antibiotics for serious infections

    by Peter M Hawkey, David M Livermore